BMO Raises Sarepta's Target Price to $50

Summary

BMO Capital Markets has raised its price target for Sarepta Therapeutics (NASDAQ:SRPT) from $25.00 to $50.00, maintaining a ‘market perform’ rating, suggesting a potential upside of 202.06% from the current price. Other analysts have varied opinions, with Guggenheim lowering its target to $98.00 and HC Wainwright reaffirming a ‘sell’ rating. Sarepta’s stock recently traded at $16.55, with a market cap of $1.63 billion. The company reported a quarterly EPS of ($3.42), missing estimates, but revenue increased by 80.2% year-over-year.Market Beat

Impact Analysis

This event is classified as a company-level event, focusing specifically on Sarepta Therapeutics. The raised price target by BMO Capital Markets to $50.00 indicates a significant potential upside compared to the current trading price of $16.55. However, the stock is under mixed analyst ratings, with some firms maintaining neutral or even negative outlooks. This suggests that investors should consider both the potential for growth indicated by BMO and the cautious perspectives of other analysts like Guggenheim and HC Wainwright, which reflect concerns about the company’s financial performance, including its recent earnings miss.Market Beat+ 3